Future Directions in Neuroblastoma Treatment
Author Information
Author(s): C.R. Pinkerton
Primary Institution: Royal Marsden Hospital
Hypothesis
Has any progress been made in the treatment of advanced neuroblastoma over the past decade?
Conclusion
High dose melphalan consolidation therapy shows a small but significant survival advantage beyond three years for neuroblastoma patients.
Supporting Evidence
- Between 1970 and 1977, only 10% of patients with advanced neuroblastoma survived 30 months after diagnosis.
- After introducing high dose melphalan, survival at 30 months improved to 35%.
- Eighteen percent of patients were alive in remission over 5 years later.
Takeaway
Doctors are trying to find better ways to treat a serious childhood cancer called neuroblastoma, and some new treatments are helping kids live longer.
Methodology
A prospective randomised study was conducted by the European Neuroblastoma Study Group to evaluate high dose melphalan consolidation therapy.
Potential Biases
Relying on historical comparisons may introduce bias in evaluating treatment effectiveness.
Limitations
The study's findings may not apply to all patients due to limited sample sizes and variations in treatment protocols.
Participant Demographics
Patients included those with stage III or IV neuroblastoma, treated at the Hospital for Sick Children.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website